- The Federal Circuit reissued its July 11 opinion in Daiichi Sankyo v. Apotex as a precedential opinion, one day after denying Daiichi's petition for rehearing. According to Hal Wegner, a major reason for making the decision precedential was Prof. Joseph Scott Miller's Rule 47.6(c) filing.
- Biosimilars legislation is "off the table" for now. The FDA bill is moving forward without it. (Bloomberg; Pharmalot).
- Novartis is set to launch its biosimilar Epoetin in Europe. (msnbc.com).
- Cubist Pharmaceuticals has asked the FDA to delist a patent on its lead product, Cubicin, from the Orange Book. (The Street.com).
- FDA issued final guidance on commercially distributed Analyte Specific Reagents, such as antibodies and nucleic acids. (FDA Law Blog).
- Dr. Reddy's and Teva settled their patent dispute over generic Zoloft. Teva had alleged that Dr. Reddy's infringed its sertraline HCl polymorph patents. (TMCnet.com).
- Imclone and Repligen/MIT settled their patent dispute over Erbitux. (Patent Prospector).
- Ranbaxy vs. Pfizer worldwide Lipitor patent litigation scorecard: mixed results. (MarketWatch.com).
- Feroz Ali Khader has written a new book on Indian patent law, particularly as it relates to pharmaceuticals. (Generic Pharmaceuticals & IP blog).
- Mr. Kapil Sibal, Honorable Minister for Science and Technology in India, will be speaking tomorrow, September 17 at 4 pm at the George Washington University Law School. (Flyer; Program).
Recent Posts
- Hikma v. Vanda: Oral Argument Recap
- Teva v. Lilly should not be read as creating a new 112 rule for method of use claims
- Should ANDA filers be using the PTAB to mount early challenges to OB patents?
- Switching to WordPress
- Judge Hughes concurrence highlights post grant review appeal standing issue for pharma cases
One response to “Pharma News Briefs”
-
This comment is directed to the subject of Ranbaxy going after the patent on Lipitor. I find it hard to believe that Pfizer is going to let the patent on the number one selling drug in the world expire 1 second early. But on the other hand, this opportunity is too big for Ranbaxy to pass up. A favorable verdict would give them exclusive rights to sell a generic version of the medicine, for a limited period, at a price that is well below Lipitor’s but gives Ranbaxy a huge profit margin.
So Ranbaxy will fight, and Pfizer will win. To the deepest pockets go the spoils.LikeLike
Orange Book Blog 
Leave a reply to Cary Cancel reply